Evidence map›Paper›PMID 40950667›Full record

ArticleTranslational cancer research2025

Enhanced antitumor efficacy of sorafenib and everolimus combination in pancreatic neuroendocrine neoplasms through mTOR inhibition.

Hongxia Zheng, Yue Gao, Mujie Ye, Jianan Bai, Min Liu, Qin Long, Jinhao Chen, Xinyun Qiang, Qiyun Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongxia Zheng *Department of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.ORCID https://orcid.org/0009-0002-9044-0220
Yue Gao *Department of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Mujie Ye *Department of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Jianan BaiDepartment of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Min LiuDepartment of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Qin LongDepartment of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Jinhao ChenDepartment of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Xinyun QiangDepartment of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
Qiyun TangDepartment of Neuroendocrine Tumor, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Institute of Neuroendocrine Tumor of Nanjing Medical University, Institute of Neuroendocrine Tumor of Collaborative Innovation Center for Cancer Personalized Medicine of Jiangsu Province, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic neuroendocrine neoplasms (pNENs) represent a rare group of highly heterogeneous tumors derived from pancreatic epithelial cells exhibiting neuroendocrine differentiation properties. Everolimus, an oral inhibitor of mTOR, is the most promising drug for patients with unresectable, metastatic disease, particularly in progressive well-differentiated pNENs. Sorafenib is utilized in the treatment of hepatocellular carcinoma (HCC), renal cell carcinoma, and differentiated thyroid cancer. Furthermore, it plays an indispensable role in the management of multisystem malignancies. This study aims to investigate the effects and mechanisms of sorafenib, as well as its potential for combination use with everolimus in pNENs. Methods: QGP-1and BON-1cells were collected from routine Results: Compared to the control group, the proliferation and migration of sorafenib-treated cells were significantly inhibited. Furthermore, as drug concentration increased, the proliferation rates of both cell types decreased. Notably, the inhibition of cell proliferation was more pronounced in the sorafenib and everolimus combination group than in the single-drug group. Western blot results indicated that the expression level of mTOR was down-regulated in the experimental group after treatment with sorafenib, everolimus, and the dual-drug combination for 24 hours, compared to the control group. In experiments involving animals, tumors in the groups treated with both high and low doses of sorafenib were smaller than those observed in the control group, and liver metastasis was suppressed in the experimental groups when compared to the control. Conclusions: Sorafenib can inhibit the proliferation and migration of pNENs by down-regulating the mTOR pathway. The combination of sorafenib and everolimus exhibits a stronger anti-tumor effect.

Indexed as

everolimusmTORPancreatic neuroendocrine neoplasms (pNENs)proliferationsorafenib

Identifiers

PMID40950667
PMCPMC12432615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.